Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Dow
McKesson
Johnson and Johnson
Harvard Business School

Last Updated: May 30, 2023

CLINICAL TRIALS PROFILE FOR BREVIBLOC


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Brevibloc

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01114971 ↗ Labetalol and Esmolol: Vital Signs and Post Operative Pain Management Completed Cedars-Sinai Medical Center Phase 4 2009-09-03 This study proposes to investigate the effects of labetalol or esmolol on managing the vital signs (like blood pressure and heart rate) during surgery, on pain management, and on the later recovery after surgery. It will also assess the cost-effectiveness of Labetalol and esmolol for outpatient surgery.
NCT01179113 ↗ Esmolol Infusion During Laminectomy: Effect on Quality of Recovery Terminated Cedars-Sinai Medical Center Phase 4 2011-06-01 The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication.
NCT01208402 ↗ Esmolol for Treatment of Perioperative Tachycardia Terminated Baxter Healthcare Corporation Phase 3 2010-09-01 The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery.
NCT01208402 ↗ Esmolol for Treatment of Perioperative Tachycardia Terminated Duke University Phase 3 2010-09-01 The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery.
NCT01232400 ↗ Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage Withdrawn University of Michigan N/A 2014-07-01 The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac function and electrophysiology; to assess the effects of esmolol treatment on serum adrenergic and cardiac biomarkers; to explore the safety of esmolol treatment shortly after subarachnoid hemorrhage (SAH). Patients will be followed for a maximum of 1 month after the index SAH. The primary outcome will be change in systolic function - ejection fraction by Simpson's rule (baseline versus Day 7 +/- 2 after SAH).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brevibloc

Condition Name

Condition Name for Brevibloc
Intervention Trials
Septic Shock 3
High-risk, Non-cardiovascular Surgeries 1
Tachycardia 1
Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Brevibloc
Intervention Trials
Shock, Septic 3
Shock 3
Tachycardia 2
Myocardial Reperfusion Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Brevibloc

Trials by Country

Trials by Country for Brevibloc
Location Trials
United States 8
Brazil 6
Turkey 3
China 1
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Brevibloc
Location Trials
Utah 2
California 2
Maryland 1
Michigan 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Brevibloc

Clinical Trial Phase

Clinical Trial Phase for Brevibloc
Clinical Trial Phase Trials
Phase 4 7
Phase 3 1
Phase 2 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Brevibloc
Clinical Trial Phase Trials
Completed 7
Unknown status 3
Withdrawn 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Brevibloc

Sponsor Name

Sponsor Name for Brevibloc
Sponsor Trials
Cedars-Sinai Medical Center 2
Baxter Healthcare Corporation 2
Beth Israel Deaconess Medical Center 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Brevibloc
Sponsor Trials
Other 19
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Johnson and Johnson
Dow
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.